(1) "Advisory committee", the Parkinson's disease registry advisory committee established in section 191.1830 to assist in the development and implementation of the registry;
(2) "Medical university", the University of Missouri and any other medical research university in the state that enters into a memorandum of understanding with the University of Missouri if deemed appropriate by the University of Missouri;
(3) "Parkinson's disease", a chronic and progressive neurologic disorder that:
(a) Results from deficiency of the neurotransmitter dopamine as the consequence of specific degenerative changes in the area of the brain called the basal ganglia;
(b) Is characterized by tremor at rest, slow movements, muscle rigidity, stooped posture, and unsteady or shuffling gait; and
(c) Includes motor and nonmotor symptoms and side effects including, but not limited to, autonomic dysfunction, thinking and mood changes, and other physical changes;
(4) "Parkinsonism", any condition that causes a combination of the movement abnormalities observed in Parkinson's disease, such as tremor at rest, slow movement, muscle rigidity, impaired speech, or muscle stiffness, with symptoms often overlapping, and that may evolve from what appears to be Parkinson's disease. The term "parkinsonism" shall include, but not be limited to, multiple system atrophy, dementia with Lewy bodies, corticobasal degeneration, and progressive supranuclear palsy;
(5) "Registry", the registry established by the medical university in section 191.1825.